Scribd Logo
Upload

Welcome to Scribd!

  • 497 views

    Finasteride

    Uploaded by

    Syokoyolanting Dondon
    Finasteride is a drug that inhibits the enzyme 5-alpha reductase, which converts testosterone to dihydrotestosterone (DHT). It is approved to treat benign prostatic hyperplasia (BPH) and male pattern baldness. By blocking DHT production, it shrinks the prostate and improves BPH symptoms. Potential side effects include sexual dysfunction and depression. The drug was developed after research found people with a genetic deficiency in 5-alpha reductase had smaller prostates and less baldness. Finasteride was approved in 1992 for BPH under the brand name Proscar and in 1997 for hair loss as Propecia.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd

    Finasteride

    Uploaded by

    Syokoyolanting Dondon
    497 views2 pages
    Finasteride is a drug that inhibits the enzyme 5-alpha reductase, which converts testosterone to dihydrotestosterone (DHT). It is approved to treat benign prostatic hyperplasia (BPH) and male pattern baldness. By blocking DHT production, it shrinks the prostate and improves BPH symptoms. Potential side effects include sexual dysfunction and depression. The drug was developed after research found people with a genetic deficiency in 5-alpha reductase had smaller prostates and less baldness. Finasteride was approved in 1992 for BPH under the brand name Proscar and in 1997 for hair loss as Propecia.

    Original Description:

    Finarid 5mg tablet

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Finasteride is a drug that inhibits the enzyme 5-alpha reductase, which converts testosterone to dihydrotestosterone (DHT). It is approved to treat benign prostatic hyperplasia (BPH) and male pattern baldness. By blocking DHT production, it shrinks the prostate and improves BPH symptoms. Potential side effects include sexual dysfunction and depression. The drug was developed after research found people with a genetic deficiency in 5-alpha reductase had smaller prostates and less baldness. Finasteride was approved in 1992 for BPH under the brand name Proscar and in 1997 for hair loss as Propecia.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    497 views2 pages

    Finasteride

    Uploaded by

    Syokoyolanting Dondon
    Finasteride is a drug that inhibits the enzyme 5-alpha reductase, which converts testosterone to dihydrotestosterone (DHT). It is approved to treat benign prostatic hyperplasia (BPH) and male pattern baldness. By blocking DHT production, it shrinks the prostate and improves BPH symptoms. Potential side effects include sexual dysfunction and depression. The drug was developed after research found people with a genetic deficiency in 5-alpha reductase had smaller prostates and less baldness. Finasteride was approved in 1992 for BPH under the brand name Proscar and in 1997 for hair loss as Propecia.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 2

    Finasteride

    Finasteride is a synthetic 5-alpha-reductase inhibitor, an inhibitor of the enzyme that converts


    testosterone to dihydrotestosterone (DHT). Finasteride is approved for the treatment of benign prostatic
    hyperplasia (BPH) and male pattern baldness (MPB).

    Benign prostatic hyperplasia

    For the treatment of BPH, aka enlarged prostate. The approved dose is 5 mg once a day for 6 months or
    more. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up
    during the night to urinate, hesitation at the start of urination, and decreased urinary flow.

    Adverse effects

    Side effects of finasteride include impotence (1.1% to 18.5%), abnormal ejaculation (7.2%), decreased
    ejaculatory volume (0.9% to 2.8%), abnormal sexual function (2.5%), gynecomastia (2.2%), erectile
    dysfunction (1.3%), ejaculation disorder (1.2%) and testicular pain. Merck added depression as a side
    effect of finasteride.[6]

    Mechanism of action

    Finasteride is an inhibitor of 5-alpha reductase. By blocking 5-alpha reductase, finasteride blocks the
    conversion of testosterone into the more powerful androgen DHT. In the prostate, inhibition of 5-alpha
    reductase leads to a reduction of prostate volume, which improves the symptoms of benign prostatic
    hyperplasia (BPH) and reduces the risk of prostate cancer.

    History

    In 1974, Julianne Imperato-McGinley of Cornell Medical College in New York attended a conference on
    birth defects. She reported on a group of hermaphroditic children in the Caribbean who appeared sexually
    ambiguous at birth, and were initially raised as girls, but then grew external male genitalia and other
    masculine characteristic post-onset of puberty. Her research group found that these children shared a
    genetic mutation, causing deficiency of the 5-alpha reductase enzyme and male hormone
    dihydrotestosterone (DHT), which was found to have been the etiology behind abnormalities in male
    sexual development. Upon maturation, these individuals were observed to have smaller prostates which
    were underdeveloped, and were also observed to lack incidence of male pattern baldness.

    In 1975, copies of Imperato-McGinley's presentation were seen by P. Roy Vagelos, who was then serving
    as Merck's basic-research chief. He was intrigued by the notion that decreased levels of DHT led to the
    development of smaller prostates. Dr. Vagelos then sought to create a drug which could mimic the
    condition found in the pseudo-hermaphroditic children in order to treat older men who were suffering
    from benign prostatic hyperplasia.

    In 1992, finasteride (5 mg) was approved by the U.S. Food and Drug Administration (FDA) for treatment
    of benign prostatic hyperplasia (BPH), which Merck marketed under the brand name Proscar.
    In 1997, Merck was successful in obtaining FDA approval for a second indication of finasteride (1 mg)
    for treatment of male pattern baldness (MPB), which was marketed under the brand name Propecia.

    You might also like